Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Helicobacter Pylori Eradication Antibiotic

Conditions

Helicobacter Pylori Eradication Antibiotic

Trial Timeline

Jun 1, 2013 → —

About Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy

Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy is a approved stage product being developed by Sun Pharmaceutical for Helicobacter Pylori Eradication Antibiotic. The current trial status is completed. This product is registered under clinical trial identifier NCT02835560. Target conditions include Helicobacter Pylori Eradication Antibiotic.

What happened to similar drugs?

1 of 3 similar drugs in Helicobacter Pylori Eradication Antibiotic were approved

Approved (1) Terminated (0) Active (2)
🔄RHB-105 + Active ComparatorRedHill BiopharmaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02835560ApprovedCompleted